These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32711543)

  • 1. Fibro-adipose vascular anomaly (FAVA): three case reports with an emphasis on the mammalian target of rapamycin (mTOR) pathway.
    Hori Y; Hirose K; Aramaki-Hattori N; Suzuki S; Nakayama R; Inoue M; Matsui T; Kohara M; Toyosawa S; Morii E
    Diagn Pathol; 2020 Jul; 15(1):98. PubMed ID: 32711543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibfibroipose vascular anomaly (FAVA).
    Hori Y; Hirose K; Ozeki M; Hata K; Motooka D; Tahara S; Matsui T; Kohara M; Higashihara H; Ono Y; Tanaka K; Toyosawa S; Morii E
    Diagn Pathol; 2022 Jan; 17(1):19. PubMed ID: 35094709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel-Trenaunay syndrome in an Asian population : List the full names and institutional addresses for all authors.
    Sasaki Y; Ishikawa K; Hatanaka KC; Oyamada Y; Sakuhara Y; Shimizu T; Saito T; Murao N; Onodera T; Miura T; Maeda T; Funayama E; Hatanaka Y; Yamamoto Y; Sasaki S
    Orphanet J Rare Dis; 2023 Sep; 18(1):270. PubMed ID: 37667289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Report of Fibro-Adipose Vascular Anomaly (FAVA) with Activating Somatic
    Driskill JH; Hwang H; Callan AK; Oliver D
    Case Rep Genet; 2022; 2022():9016497. PubMed ID: 35967928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibro-adipose vascular anomaly (FAVA) - diagnosis, staging and management.
    Wang H; Xie C; Lin W; Wang P; Yang W; Guo Z
    Orphanet J Rare Dis; 2023 Nov; 18(1):347. PubMed ID: 37936141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
    Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
    Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibro-adipose vascular anomaly: clinical-radiologic-pathologic features of a newly delineated disorder of the extremity.
    Alomari AI; Spencer SA; Arnold RW; Chaudry G; Kasser JR; Burrows PE; Govender P; Padua HM; Dillon B; Upton J; Taghinia AH; Fishman SJ; Mulliken JB; Fevurly RD; Greene AK; Landrigan-Ossar M; Paltiel HJ; Trenor CC; Kozakewich HP
    J Pediatr Orthop; 2014 Jan; 34(1):109-17. PubMed ID: 24322574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Treatment of Fibro-Adipose Vascular Anomaly with Sirolimus.
    Wang Z; Yan H; Ding Y; Gong Y; Ma Y; Yao W; Li K
    J Pediatr Surg; 2023 Jul; 58(7):1337-1341. PubMed ID: 36898877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of mTOR pathway expression in lymphatic malformation and related diseases.
    Hori Y; Ozeki M; Hirose K; Matsuoka K; Matsui T; Kohara M; Tahara S; Toyosawa S; Fukao T; Morii E
    Pathol Int; 2020 Jun; 70(6):323-329. PubMed ID: 32067331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.
    di Blasio L; Puliafito A; Gagliardi PA; Comunanza V; Somale D; Chiaverina G; Bussolino F; Primo L
    Cell Death Dis; 2018 Jan; 9(2):45. PubMed ID: 29352118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
    Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
    Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroadipose vascular anomaly: a clinicopathological study of 75 cases.
    Xue S; Liu Q; Zhao Y; Kong L; Fu F; Gong Y; Guo X; Dong C; Wang M
    Histopathology; 2023 Aug; 83(2):286-297. PubMed ID: 37099413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
    Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
    Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibro-Adipose Vascular Anomaly (FAVA): Not Another Vascular Anagram.
    Barwad A; Narwal A; Dutta R; Behera R; Kumar VS; Rastogi S; Mridha AR
    Int J Surg Pathol; 2023 Jul; ():10668969231188419. PubMed ID: 37461272
    [No Abstract]   [Full Text] [Related]  

  • 16. Somatic activating mutations in
    Rodriguez-Laguna L; Agra N; Ibañez K; Oliva-Molina G; Gordo G; Khurana N; Hominick D; Beato M; Colmenero I; Herranz G; Torres Canizalez JM; Rodríguez Pena R; Vallespín E; Martín-Arenas R; Del Pozo Á; Villaverde C; Bustamante A; Ayuso C; Lapunzina P; Lopez-Gutierrez JC; Dellinger MT; Martinez-Glez V
    J Exp Med; 2019 Feb; 216(2):407-418. PubMed ID: 30591517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors.
    Loconte DC; Grossi V; Bozzao C; Forte G; Bagnulo R; Stella A; Lastella P; Cutrone M; Benedicenti F; Susca FC; Patruno M; Varvara D; Germani A; Chessa L; Laforgia N; Tenconi R; Simone C; Resta N
    PLoS One; 2015; 10(4):e0123092. PubMed ID: 25915946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA.
    Luks VL; Kamitaki N; Vivero MP; Uller W; Rab R; Bovée JV; Rialon KL; Guevara CJ; Alomari AI; Greene AK; Fishman SJ; Kozakewich HP; Maclellan RA; Mulliken JB; Rahbar R; Spencer SA; Trenor CC; Upton J; Zurakowski D; Perkins JA; Kirsh A; Bennett JT; Dobyns WB; Kurek KC; Warman ML; McCarroll SA; Murillo R
    J Pediatr; 2015 Apr; 166(4):1048-54.e1-5. PubMed ID: 25681199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower Extremity Fibro-Adipose Vascular Anomaly-Case Report.
    Ferreira J; López Gutiérrez JC; Carneiro A; Sousa PP; Braga S; Simões JC; Carrilho C; Mesquita A
    Ann Vasc Surg; 2020 Jul; 66():671.e15-671.e18. PubMed ID: 32018020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations.
    Blesinger H; Kaulfuß S; Aung T; Schwoch S; Prantl L; Rößler J; Wilting J; Becker J
    PLoS One; 2018; 13(7):e0200343. PubMed ID: 29985963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.